Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Capital Expenditures: 2009-2024

Historic Capital Expenditures for Cytokinetics (CYTK) over the last 16 years, with Dec 2024 value amounting to $3.9 million.

  • Cytokinetics' Capital Expenditures rose 1234.38% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 659.49%. This contributed to the annual value of $3.9 million for FY2024, which is 175.85% up from last year.
  • Latest data reveals that Cytokinetics reported Capital Expenditures of $3.9 million as of FY2024, which was up 175.85% from $1.4 million recorded in FY2023.
  • Cytokinetics' Capital Expenditures' 5-year high stood at $48.9 million during FY2021, with a 5-year trough of $1.4 million in FY2023.
  • For the 3-year period, Cytokinetics' Capital Expenditures averaged around $5.6 million, with its median value being $3.9 million (2024).
  • Per our database at Business Quant, Cytokinetics' Capital Expenditures surged by 342.20% in 2021 and then plummeted by 87.51% in 2023.
  • Yearly analysis of 5 years shows Cytokinetics' Capital Expenditures stood at $11.1 million in 2020, then soared by 342.20% to $48.9 million in 2021, then slumped by 76.81% to $11.3 million in 2022, then slumped by 87.51% to $1.4 million in 2023, then soared by 175.85% to $3.9 million in 2024.